Preconception resveratrol intake against infertility: Friend or foe?

Asako Ochiai, Ochiai A, Keiji Kuroda
Reproductive medicine and biology · 2019 · vol. 19(2) , pp. 107–113 · doi:10.1002/rmb2.12303 · PMID:32273814 · PMC7138940 · W2979985696
review OA: gold CC0 ⤵ 7 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This review examines resveratrol's beneficial effects on ovarian function by upregulating SIRT1 and improving mitochondrial function, but also its detrimental impact on endometrial receptivity and potential teratogenicity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This paper is a review of preconception resveratrol intake and its potential effects on infertility, focusing mainly on ovarian aging, primary ovarian insufficiency, polycystic ovary syndrome, IVF outcomes, and endometrial decidual biology, drawing largely from animal and in vitro studies plus limited human trial data. It reports that resveratrol may protect ovarian reserve and function via SIRT1 activation, reduce oxidative stress/inflammation, and improve oocyte maturation and embryo developmental competence in culture, while also noting that human evidence is limited to few trials and that implantation could theoretically be impaired because resveratrol is described as an anti-inflammatory/anti-senescence agent that might interfere with necessary inflammatory and senescence-related processes of decidualization. A key caveat emphasized is the scarcity of human fertility outcome data, especially regarding endometrium and pregnancy endpoints. Resveratrol is discussed in relation to endometriosis via reports that it can inhibit progression of ectopic endometrium, even though the paper is primarily a broad infertility review of resveratrol’s reproductive and pregnancy effects rather than an endometriosis-only analysis. This paper is centrally about endometriosis — it specifically discusses resveratrol’s reported inhibition of progression of ectopic endometrium (endometriosis) and potential effects on infertility with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: Resveratrol is an antiaging, antioxidant, anti-inflammatory, and insulin-sensitizing natural polyphenolic compound. Growing evidence indicates that resveratrol has potential therapeutic effects in infertile women with diminished ovarian function, polycystic ovary syndrome (PCOS), or endometriosis. However, only one clinical trial in women undergoing in vitro fertilization (IVF) cycles using resveratrol has ever been reported. This review focuses on the potential therapeutic effects of resveratrol on pregnancy and on its advantages and disadvantages in pregnancy outcomes during infertility treatment. METHODS: We performed a literature review to describe the known impacts of resveratrol on the ovary and endometrium. RESULTS: Resveratrol upregulates sirtuin (SIRT)1 expression in ovaries, which is associated with protection against oxidative stress. It leads to the activation of telomerase activity and mitochondrial function, improving ovarian function. In the endometrium, resveratrol downregulates the CRABP2-RAR pathway leading to suppressing decidual and senescent changes of endometrial cells, which is essential for embryo implantation and placentation. Moreover, resveratrol may also induce deacetylation of important decidual-related genes. CONCLUSIONS: Resveratrol has potential therapeutic effects for improving ovarian function; however, it also has anti-deciduogenic actions in uterine endometrium. In addition, its teratogenicity has not yet been ruled out; thus, resveratrol should be avoided during the luteal phase and pregnancy.
Full text 19,152 characters · extracted from pmc-nxml · 5 sections · click to expand

Impact

Successful pregnancy requires endometrial receptivity with optimal decidualization and synchronization with developmentally competent embryos. 47 Decidualization consists in cellular morphological changes of the human endometrial stromal cells (HESCs) accompanied by integrated gene expression alterations, such as those of prolactin (PRL) and insulin‐like growth factor‐binding protein‐1 (IGFBP‐1), generating an implantation window. 47 , 48 During decidualization, the endometrium is receptive for implantation and maintenance of pregnancy, resists oxidative stress, and promotes immune tolerance by modulating a local inflammatory reaction to allow trophoblast invasion. By contrast, impaired decidualization causes a variety of pre‐ and post‐pregnancy disorders, such as implantation failure, pregnancy loss, and uteroplacental dysfunction. 47 , 49 , 50 , 51 The evidence for the effects of resveratrol on the human endometrium is still limited. Resveratrol promotes calcium‐dependent, cell adhesion–related gene E‐cadherin expression via increased expression of SIRT1 in Ishikawa cells, which means it can induce embryo attachment to the endometrium. 52 Also, resveratrol has antiapoptosis and antiproliferative effects, and it can inhibit progression of ectopic endometrium (endometriosis). 6 These reports suggest beneficial therapeutic effects of resveratrol on infertility with endometriosis. However, implantation requires an inflammatory reaction with local secretion of proinflammatory cytokines and prostaglandins from the decidualized endometrium. 53 , 54 , 55 Resveratrol has anti‐inflammatory actions that may suppress embryo implantation directly. The decidualization of endometrial stromal cells does not entail only cellular differentiation; the alteration requires a combination of differentiation and apoptosis/senescence. 56 , 57 , 58 In fact, decidual cells secrete proapoptotic factors during the decidualization of HESCs. 58 In in vitro primary cultures, the decidualization of HESCs induces senescence‐associated β‐galactosidase (SAβG) activity and increases expressions of major senescent markers, including p16 and p53. 56 , 57 Decidual cells secrete inflammatory mediators associated with endometrial receptivity, through acute cellular senescence. In addition, pro‐senescent decidual cells are cleared by uterine natural killer (uNK) cells (the most abundant immune cells in the decidualized endometrium) for remodeling and rejuvenating the environment. 57 A suppressor of cellular senescence, the mTOR inhibitor rapamycin inhibits SAβG‐positive cells, expression of senescent markers, and decidualization, leading to reduced expression of decidual marker genes, PRL and IGFBP1 . 57 Resveratrol as an anti‐senescence agent also has potential adverse effects on the decidua of humans and may impair implantation and pregnancy. Decidual changes of HESCs depend on orchestrated reprogramming of various pathways, including that of retinoic acid (RA) signaling. 47 , 59 Retinoic acid regulates two opposing cell fates, differentiation and apoptosis, by binding to cellular RA‐binding proteins, CRABP2 or FABP5, and getting activated by the nuclear receptors (retinoic acid receptor, RAR) to promote the activation of genes involved in apoptotic machinery and cell cycle arrest, or by peroxisome the proliferator‐activated receptor (PPAR) β/δ to promote cell differentiation. Decidualization of HESCs downregulates RA signaling via a decrease in cytoplasmic binding proteins, CRABP2 and FABP5. Moreover, RA‐binding receptors, RAR and PPARβ/δ, are induced and suppressed by decidualization, respectively. Therefore, decidualization of HESCs requires an appropriate suppression of the proapoptotic CRABP2‐RAR signaling pathway. 59 SIRT1 is an important modulator of RA signaling, and it interacts with and deacetylates CRABP2 60 and also inhibits the transcriptional activity of RAR. 61 Our previous study demonstrated that resveratrol treatment accelerates downregulation of the CRABP2‐RAR pathway in decidualized HESCs, leading to decreasing SAβG activity and expression of p53. 56 In addition, decidual markers were inhibited in decidual cells treated with resveratrol 56 (Figure 2 ). Impaired decidualization causes implantation failure and pregnancy loss. 49 Moreover, decidualization of HESCs is associated with epigenetic changes, including H3K27 acetylation of promoter regions in decidual markers PRL and IGFBP1. 62 , 63 , 64 , 65 , 66 SIRT1 has histone deacetylation effects on decidual‐related genes (PRL, IGFBP1, p53, and FOXO‐family). 60 , 67 , 68 , 69 , 70 Thus, resveratrol supplementation may inhibit decidual senescence and induce deacetylation of important decidual‐related genes, leading to decreasing endometrial receptivity, in the clinical practice (Figure 2 ). Resveratrol has potential therapeutic effects in women with diminished ovarian reserve and function through its suppression of oxidative stress and its stimulation of mitochondrial biogenesis, but it also has adverse effects on implantation and endometrial decidualization. Is resveratrol “a friend or a foe” for pregnancy? We evaluated the impact of resveratrol on human pregnancy outcomes during IVF‐embryo transfer (ET) cycles for the first time and found poor outcomes. 10 The retrospective cross‐sectional study was carried out to compare the pregnancy outcomes after ET cycles between women with infertility using resveratrol (200 mg per day) continuously (RES group) and women in a control group not using any (non‐RES group). Our multivariate logistic regression analysis demonstrated that resveratrol intake was significantly associated with low clinical pregnancy rates (post‐adjusted odds ratio [OR] 0.539, 95% confidence interval [CI] 0.341‐0.853) and high miscarriage rates (OR 2.602, 95% CI 1.070‐6.325). In agreement with the effects of the senescence suppressor on decidualization in primary cultures, resveratrol intake may adversely impact pregnancy outcomes following ET cycles. In our clinical study, the patients in the RES group had poor pregnancy outcomes after ET even though embryos with good quality were transferred. However, in some patients with impaired ovarian reserve, resveratrol supplementation may improve oocyte quality and quantity leading to the collection of competent embryos. Our study focused on pregnancy outcomes after ET, and we had no data on ovarian function before and after resveratrol intake. Resveratrol treatment has been shown to protect against ovarian aging and to improve PCOS and endometriosis; 4 , 5 , 6 therefore, resveratrol intake may have benefits for some patients. Based on these data, when using resveratrol during infertility treatments, if the tissue level of resveratrol vanishes in the endometrium before decidualization, it may not adversely affect implantation or pregnancy. In humans, the half‐life of resveratrol is only 9‐10 hours. 71 , 72 We tested this hypothesis on decidualized primary HESCs with or without treatment with 100 μmol/L of resveratrol or pre‐treating cells with resveratrol for 48 hours followed by wash‐off and decidualization without resveratrol treatment (Figure 3 ); our results showed that resveratrol treatment suppressed PRL and IGFBP1 expression, but the pre‐treatment had no impact on the induction of decidual markers. 56 Thus, in the clinical practice, discontinuation of resveratrol intake at the beginning of the luteal phase (the day of ovulation) or cryopreservation of all embryo (freeze‐all policy) and warmed ET without supplementation (Figure 4 ) should help overcome these adverse effects. In all, a randomized controlled trial is needed to evaluate the use of resveratrol as an infertility treatment. Pre‐treatment with resveratrol does not inhibit decidual marker genes in the decidualized endometrium. Real‐time quantitative PCR analysis of decidual markers PRL and IGFBP1 in human endometrial stromal cells (treated with 8‐bromoadenosine‐cAMP and progesterone (P4) with or without 100 μmol/L of resveratrol for 4 or 8 days and pre‐treatment of the cells with resveratrol for 48 h followed by wash‐off and decidualization without resveratrol treatment) showing fold changes (mean ± SEM) in PRL and IGFBP1 transcript levels relative to negative control (from four independent primary cultures). Different letters above the error bars suggest groups that are significantly different from each other at P  < .05. This is a modified graph from our previous reports (Ochiai et al 56 ) Recommendations for resveratrol supplementation in IVF treatment. We recommend discontinuation of resveratrol intake at the beginning of the luteal phase (the day of ovulation) or cryopreservation of all embryos (freeze‐all policy) and vitrified and warmed ET without supplementation

Possible

Resveratrol does not appear to produce severe side effects at doses <1.0 g/day in various in vivo and in vitro studies with a wide range of resveratrol doses, whereas doses ≥1.0 g may produce side effects, including headache, dizziness, nausea, diarrhea, and liver dysfunction. 73 , 74 , 75 , 76 In a phase 2 clinical study, resveratrol intake at doses of 5.0 g in patients with refractory multiple myeloma caused severe renal failure in 5 of 24 patients before the study was stopped. 77 However, other clinical studies in patients with colorectal cancer and healthy volunteers did not show any nephrotoxicity at the same dose of resveratrol. 78 , 79 The renal failure may have been caused by the progression of multiple myeloma, but as a precaution, high‐dose resveratrol should not be administered to infertile women. Although little is known about the maternal and fetal effects of resveratrol, its supplementation should be discontinued during pregnancy, based on the adverse decidualization effects in the human endometrium.

Conclusions

Women with advanced age face difficulties in getting pregnant due to decreased quality and quantities in their oocytes. Resveratrol has potential therapeutic effects for improving ovarian function; however, it also has anti‐deciduogenic actions. Moreover, its teratogenicity has not yet been ruled out; therefore, resveratrol should be avoided during the luteal phase and pregnancy. Further clinical studies are needed to establish optimal doses and periods of resveratrol intake while preventing adverse effects on implantation, subsequent pregnancy, and the fetus.

Introduction

Resveratrol (trans‐3, 5, 40‐trihydroxystilbene) is a natural polyphenolic compound, detected in a variety of plants, foods, and drinks, such as grapes, nuts, cranberries, and red wine. 1 Resveratrol has beneficial effects on human health, including antiaging, antioxidant, anti‐inflammatory, insulin‐sensitizing, cardioprotective, vasodilating, and anti‐neoplastic properties 2 (Figure 1 ). Therefore, resveratrol intake can improve metabolic diseases, such as obesity, diabetes mellitus, and hypertension, and reduce the risk of cardiovascular diseases and malignant neoplasm. 3 Growing evidence indicates that resveratrol has potential therapeutic effects in women with diminished ovarian function, polycystic ovary syndrome (PCOS), endometriosis, or uterine fibroids. 4 , 5 , 6 , 7 In addition, resveratrol may improve testicular function and sperm quality. 8 , 9 Therefore, resveratrol supplementation may help to treat both male and female infertility based on animal studies. However, in humans, only a single clinical trial on resveratrol for women undergoing in vitro fertilization (IVF) cycles has been carried out. 10 Our review discusses the potential therapeutic effects of resveratrol on pregnancy and its advantages and disadvantages for pregnancy outcomes during infertility treatment. Effects of resveratrol on human health. Resveratrol has beneficial effects on human health, including antiaging, antioxidant, anti‐inflammatory, insulin‐sensitizing, cardioprotective, vasodilating, and anti‐neoplastic properties

Coi Statement

Human/Animal rights: This article does not contain any studies with human and animal subjects performed by any of the authors.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (84)

Cited by (7)

Source provenance

europepmc
last seen: 2026-08-03T06:10:56.557307+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:05.164793+00:00
License: CC0 · commercial use OK